Global Health Investment Corporation
GHIC is a nonprofit venture investor that mobilizes private, philanthropic and public capital to accelerate development, commercialization, and access to vaccines, therapeutics, diagnostics, medical devices and other health technologies that address global public health needs, health equity, and health security. GHIC operates an impact investment fund (GHIF), manages a public–private venture partnership with BARDA to finance health security technologies, and runs grant and catalytic investment initiatives to seed early-stage research and funds.
Global Health Investment Corporation
New York, New York, United States, North America
Services
Direct venture equity investments
Makes direct equity investments in life sciences and health technology companies across seed to growth stages to accelerate development and commercialization of products with global health impact.
Partnership-managed public capital deployment (BARDA Ventures partnership)
Manages and deploys BARDA Ventures funding alongside matched capital from public, philanthropic and private sources to invest in companies developing medical countermeasures and health security technologies.
Anchor limited partner investments and fund-of-funds activity
Provides anchor or limited partner capital to third‑party funds (for example an anchor investment in the Women’s and Children’s Health Technology Fund and investment in AfricInvest’s Transform Health Fund via CHIP).
Non-dilutive research funding and fellowships (Frontier Fund)
Operates a non-dilutive $20M Frontier Fund to provide flexible research funding, consortium awards, and early-investigator fellowships to seed high-risk, high-impact global health security research and translational projects.
Catalytic blended finance platform (CHIP)
Runs the Catalytic Health Investment Platform (CHIP), a 20-year partnership with KfW/BMZ to make catalytic investments and grants focused on public health technologies and health system resilience in LMICs.
Strategic partnerships and technical convening
Forms strategic collaborations (examples: BARDA, MITRE, CEPI) to integrate technical evaluation, funding, and commercialization support for portfolio companies and to align investments with public health priorities.
Direct venture equity investments
Makes direct equity investments in life sciences and health technology companies across seed to growth stages to accelerate development and commercialization of products with global health impact.
Partnership-managed public capital deployment (BARDA Ventures partnership)
Manages and deploys BARDA Ventures funding alongside matched capital from public, philanthropic and private sources to invest in companies developing medical countermeasures and health security technologies.
Anchor limited partner investments and fund-of-funds activity
Provides anchor or limited partner capital to third‑party funds (for example an anchor investment in the Women’s and Children’s Health Technology Fund and investment in AfricInvest’s Transform Health Fund via CHIP).
Non-dilutive research funding and fellowships (Frontier Fund)
Operates a non-dilutive $20M Frontier Fund to provide flexible research funding, consortium awards, and early-investigator fellowships to seed high-risk, high-impact global health security research and translational projects.
Catalytic blended finance platform (CHIP)
Runs the Catalytic Health Investment Platform (CHIP), a 20-year partnership with KfW/BMZ to make catalytic investments and grants focused on public health technologies and health system resilience in LMICs.
Strategic partnerships and technical convening
Forms strategic collaborations (examples: BARDA, MITRE, CEPI) to integrate technical evaluation, funding, and commercialization support for portfolio companies and to align investments with public health priorities.
Portfolio
GHIF portfolio company; developed Jada system for postpartum hemorrhage. Acquired by Organon (announcement June 16, 2021).
#Medical devices / maternal health
GHIC participated in Biolinq's $100M Series B round; initial global health security portfolio investment under the BARDA partnership. Senior Advisor to GHIC joined Biolinq board (Zina Affas Besse).
#Wearable biosensors / diagnostics
GHIC participated in a financing to support Endpoint Health's precision therapeutics platform and to advance its Antithrombin III program toward Phase II for sepsis.
#Therapeutics / precision immunology
GHIC participated in the first close of a €44M Series D to support biologics manufacturing capabilities and global expansion.
#Biologics manufacturing / biomanufacturing
GHIC invested $2M as a strategic investor in Vaxess's Series B; Vaxess developing MIMIX sustained-release vaccine patch and advancing a Phase 1 influenza vaccine patch trial.
#Vaccine delivery / patches
GHIC participated in a $25M seed round to advance Monod's de novo protein-based biosensor LucCage platform for rapid point-of-care diagnostics.
#Diagnostics / biosensors
GHIF portfolio company; developed Jada system for postpartum hemorrhage. Acquired by Organon (announcement June 16, 2021).
#Medical devices / maternal health
GHIC participated in Biolinq's $100M Series B round; initial global health security portfolio investment under the BARDA partnership. Senior Advisor to GHIC joined Biolinq board (Zina Affas Besse).
#Wearable biosensors / diagnostics
GHIC participated in a financing to support Endpoint Health's precision therapeutics platform and to advance its Antithrombin III program toward Phase II for sepsis.
#Therapeutics / precision immunology
GHIC participated in the first close of a €44M Series D to support biologics manufacturing capabilities and global expansion.
#Biologics manufacturing / biomanufacturing
GHIC invested $2M as a strategic investor in Vaxess's Series B; Vaxess developing MIMIX sustained-release vaccine patch and advancing a Phase 1 influenza vaccine patch trial.
#Vaccine delivery / patches
GHIC participated in a $25M seed round to advance Monod's de novo protein-based biosensor LucCage platform for rapid point-of-care diagnostics.
#Diagnostics / biosensors